Gene manipulation to enhance MIBG-targeted radionuclide therapy

The goal of targeted radionuclide therapy is the deposition in malignant cells of sterilizing doses of radiation without damaging normal tissue. The radiopharmaceutical [ 131I] meta-iodobenzylguanidine ([ 131I]MIBG) is an effective single agent for the treatment of neuroblastoma. However, uptake of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nuclear medicine and biology 2005-10, Vol.32 (7), p.749-753
Hauptverfasser:	Mairs, Robert J., Fullerton, Natasha E., Cosimo, Emilio, Boyd, Marie
Format:	Artikel
Sprache:	eng
Schlagworte:	3-Iodobenzylguanidine - therapeutic use Animals Drug Delivery Systems - methods Gene Targeting - methods Gene therapy Genetic Therapy - methods Humans MIBG Neuroblastoma - genetics Neuroblastoma - radiotherapy Noradrenaline transporter Norepinephrine Plasma Membrane Transport Proteins - genetics Radiopharmaceuticals - therapeutic use Radiotherapy - methods Targeted radiotherapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The goal of targeted radionuclide therapy is the deposition in malignant cells of sterilizing doses of radiation without damaging normal tissue. The radiopharmaceutical [ 131I] meta-iodobenzylguanidine ([ 131I]MIBG) is an effective single agent for the treatment of neuroblastoma. However, uptake of the drug in malignant sites is insufficient to cure disease. A growing body of experimental evidence indicates exciting possibilities for the integration of gene transfer with [ 131I]MIBG-targeted radiotherapy.
ISSN:	0969-8051 1872-9614
DOI:	10.1016/j.nucmedbio.2005.03.011